INVION LIMITED — Capital/Financing Update 2015

Mar 29, 2015

ASX / MEDIA ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

30 March 2015

Entitlement Offer –

Despatch of information booklet and entitlement & acceptance form

Invion Limited (ASX: IVX) confirms that the entitlement offer information booklet and entitlement and acceptance form relating to its non-renounceable entitlement offer, announced on 20 March 2015, has been despatched to eligible shareholders today.

Further information

If you have any queries, please call 1300 859 277 (inside Australia) or +61 1300 859 277 (outside Australia) or, alternatively, consult your professional adviser.

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the - build-up of mucus in the lungs. INV103 (ala Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA.

Invion Limited ABN 76 094 730 417

GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com